N Colombo

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olapari...

Annals of oncology : official journal of the European Society for Medical Oncology · 2026-04

Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial.

European journal of cancer (Oxford, England : 1990) · 25 juli 2025

Efficacy of subsequent therapies in patiënten met gevorderd ovarian cancer who relapse after eerstelijns olaparib mai...

Annals of oncology : official journal of the European Society for Medical Oncology · 2025-02

Pembrolizumab plus chemotherapie bij gevorderd cervixcarcinoom: KEYNOTE-826 definitieve analyse

Annals of oncology : official journal of the European Society for Medical Oncology · 2025-01

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvan...

Annals of oncology : official journal of the European Society for Medical Oncology · 2024-11

Immunotherapie plus eerstelijns bij gevorderd endometriumcarcinoom: overzicht

Annals of oncology : official journal of the European Society for Medical Oncology · 2024-05

Olaparib-rechallenge als onderhoud bij recidief ovariumcarcinoom na eerdere PARP: OReO/ENGOT-ov38 langetermijn

Annals of oncology : official journal of the European Society for Medical Oncology · 2023-12

Olaparib plus bevacizumab onderhoud bij ovariumcarcinoom: PAOLA-1 definitieve OS

Annals of oncology : official journal of the European Society for Medical Oncology · 2023-08

Risicoreductie en screening bij hereditair borst-/ovariumcarcinoom: ESMO 2022 richtlijn

Annals of oncology : official journal of the European Society for Medical Oncology · 2023-01

Chemotherapie-werkzaamheid bij BRCA-gemuteerd recidief ovariumcarcinoom na PARP-remmer

Annals of oncology : official journal of the European Society for Medical Oncology · 2022-10

Endometriumcarcinoom: ESMO 2022 richtlijn

Annals of oncology : official journal of the European Society for Medical Oncology · 2022-09

Mirvetuximab soravtansine versus chemotherapie bij platinaresistent ovariumcarcinoom: FORWARD I fase III

Annals of oncology : official journal of the European Society for Medical Oncology · 2021-06

ESMO-ESGO consensus over ovariumcarcinoom: pathologie, moleculaire biologie en stadiëring

Annals of oncology : official journal of the European Society for Medical Oncology · 1 mei 2019

Niet-epitheliaal ovariumcarcinoom: ESMO-richtlijn

Annals of oncology : official journal of the European Society for Medical Oncology · 1 oktober 2018

Veiligheid en dosismodificatie bij niraparib: praktische aanbevelingen

Annals of oncology : official journal of the European Society for Medical Oncology · 1 augustus 2018

Cervixcarcinoom: ESMO-richtlijn voor diagnostiek, behandeling en follow-up

Annals of oncology : official journal of the European Society for Medical Oncology · 1 juli 2017

Endometriumcarcinoom: ESMO eUpdate

Annals of oncology : official journal of the European Society for Medical Oncology · 1 juli 2017

Fertiliteitssparende chirurgie bij epitheliaal ovariumcarcinoom: systematische review van oncologische kwesties

Annals of oncology : official journal of the European Society for Medical Oncology · 2016-11